Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc.
Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026
Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027
Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T.
March 27, 2024 -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced it has acquired a Phase